DOCSLIB.ORG

RESTRICTED ACCORD GENERAL SUR LES TARIFS TAR/W/87/Rev.L 16 Juin 1994 DOUANIERS ET LE COMMERCE Distribution Limitée Comité

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RESTRICTED ACCORD GENERAL SUR LES TARIFS TAR/W/87/Rev.L 16 Juin 1994 DOUANIERS ET LE COMMERCE Distribution Limitée Comité RESTRICTED ACCORD GENERAL SUR LES TARIFS TAR/W/87/Rev.l 16 juin 1994 DOUANIERS ET LE COMMERCE Distribution limitée (94-1266) Comité des concessions tarifaires SYSTEME HARMONISE DE DESIGNATION ET DE CODIFICATION DES MARCHANDISES (Système harmonisé) Classification des substances PCI Révision La Direction de la nomenclature et de la classification du Conseil de coopération douanière (Bruxelles) a fait parvenir au secrétariat la communication ci-après. Le 25 mai 1993, nous vous avons adressé une liste des substances DCI dont la classification avait été examinée et arrêtée par le Comité du Système harmonisé et nous vous avons également informé que la classification de deux substances, le clobénoside et le méclofénoxate, serait arrêtée ultérieurement. Par ailleurs, une partie contractante avait émis une réserve au sujet de certains produits chimiques figurant sur cette liste et le Comité du Système harmonisé a donc réexaminé la décision qu'il avait prise antérieurement dans le cas de ces produits. Vous trouverez par conséquent ci-joint une liste révisée complète des décisions concernant la classification des substances DCI. Deux substances y ont été ajoutées et deux autres ont été reclassées, ainsi qu'il est indiqué ci-après: a) Addition Classification du clobénoside (sous-position 2940.00) et du méclofénoxate (sous-position 2922.19). b) Modification L'étafédrine et la moxidectine sont maintenant reclassées dans les sous-positions 2939.40 et 2932.29, respectivement. La liste des substances DCI reproduite ci-après n'est disponible qu'en anglais. TAR/W/87/Rev.l Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HSCodi 1 acarbose 2932.90 2 acemannan 3913.90 3 aciclovir 2933.59 4 acipimox 2933.90 5 acitretin 2918.90 6 aclantate 2934.90 7 acrisorcin 2933.90 8 acrivastine 2933.39 9 acrocinonide 2937.22 10 adibendan 2933.79 11 alclofenac 2918.90 12 aldesleukin 3504.00 13 alfacalcidol 2936.10 14 alfentanil 2933.39 15 allopurinol 2933.59 16 almagate 2842.90 17 aloxistatin 2924.29 18 alpertine 2933.59 19 altapizone 2933.39 20 altizide 2935.00 21 ambasilide 2933.39 22 ambruticin 2941.90 23 amcinafal 2937.22 24 amcinafide 2937.22 25 amcinonide 2937.22 26 amebucort 2937.29 27 amfomycin 2941.90 28 aminoethyl nitrate 2922.50 29 amopyroquine 2933.40 30 amphenidone 2933.79 31 amylmetacresol 2907.19 32 anagestone 2937.92 33 anaritide 2934.90 34 anaxirone 2934.90 35 anazocine 2933.39 36 ancrod 3507.90 37 angiotensinamide 2933.29 38 anistreplase 3507.90 39 antazonite 2934.10 40 aptazapine 2933.59 41 arbekacin 2941.90 42 arfalasin 2933.29 43 arginine 2925.20 44 arnolol 2922.19 TAR/W/87/Rev.l Page 3 Description HS Code 45 arotinolol 2934.10 46 arprinocid 2933.59 47 asobamast 2934.10 48 astemizole 2933.39 49 atamestane 2937.99 50 atiprosin 2933.59 51 atrimustine 2922.50 52 atromepine 2939.90 53 azabon 2935.00 54 azatadine 2933.39 55 azathioprine 2933.59 56 azetirelin 2937.99 57 benfurodil hemisuccinate 2932.29 58 benolizime 2933.90 59 benperidol 2933.39 60 bentemazole 2933.29 61 benzindopyrine 2933.39 62 benzopyrronium bromide 2933.90 63 betiatide 2930.90 64 bezafibrate 2924.29 65 binfloxacin 2933.40 66 binizolast 2933.59 67 bisaramil 2933.39 68 brazergoline 2939.60 69 bremazocine 2933.39 70 brifentanil 2933.39 71 bromerguride 2939.60 72 bromhexine 2921.59 73 bromindione 2914.70 74 broperamole 2933.39 75 buciclovir 2933.59 76 budesonide 2937.29 77 budotitane 2914.49 78 bumepidil 2933.59 79 bunaprolast 2915.39 80 bunazosin 2933.59 81 buquiterine 2933.59 82 buserelin 2937.99 83 buthalital sodium 2933.59 84 butixocort 2937.29 85 calcium carbimide 3102.70 86 carbasalate calcium 2924.29 87 carbazocine 2933.40 88 carbetimer 3911.90 89 carboplatin 2843.90 90 carfenazine 2934.30 91 carmofur 2933.59 92 carumonam 2941.90 93 cefquinome 2941.90 94 cefteram 2941.90 TAR/W/87/Rev.l Page 4 Description HS Cod< 95 cefiizonam 2941.90 96 chlorotrianisene 2909.30 97 ciclesonide 2937.29 98 cilobradine 2933.79 99 cilofungin 2941.90 100 cismadinone 2937.92 101 cliropamine 2922.50 102 clobenoside 2940.00 103 cloxestradiol 2937.92 104 cortodoxone 2914.49 105 crilvastatin 2933.79 106 crisnatol 2922.19 107 cromakalim 2934.90 108 crotoniazide 2933.39 109 dalbraminol 2933.19 110 daniquidone 2933.79 111 decitropine 2939.90 112 declenperone 2933.39 113 deflazacort 2937.29 114 deloxolone 2918.19 115 demegestone 2937.92 116 denbufylline 2939.50 117 derpanicate 2933.39 118 desciclovir 2933.59 119 descinolone 2937.22 120 deslanoside 2938.90 121 desmopressin 2937.99 122 desoximetasone 2937.22 123 dextromethorphan 2933.40 124 dextrorphan 2933.40 125 dezaguanine 2933.79 126 dichlorisone 2937.22 127 diciferron 2931.00 128 dicirenone 2937.99 129 dicobalt edetate 2922.49 130 dienestrol 2907.29 131 dienogest 2937.92 132 diethylstilbestrol 2907.29 133 difenoximide 2933.39 134 difluprednate 2937.22 135 diltiazem 2934.90 136 dimabefylline 2939.50 137 dimelazine 2934.30 138 dimesone 2937.22 139 diprogulic acid 2932.90 140 dirithromycin 2941.50 141 disogluside 2938.90 142 disulfiram 2930.30 143 disuprazole 2933.39 144 ditekiren 2933.39 TAR/W/87/Rev.l Page 5 Description HSCode 145 ditercalinium chloride 2933.39 146 dithranol 2914.50 147 divaplon 2933.59 148 dizocilpine 2933.40 149 docetaxol 2932.90 150 domoprednate 2937.29 151 domperidone 2933.39 152 doqualast 2933.59 153 doramectin 2941.90 154 dorastine 2933.39 155 dosergoside 2939.60 156 draquinolol 2933.79 157 drospirenone 2932.29 158 drotebanol 2933.40 159 duteplase 3507.90 160 ecogramostim 3504.00 161 ecomustine 2932.90 162 edelfosine 2923.90 163 edifolone 2932.90 164 elliptinium acetate 2939.90 165 elsamitrucin 2941.90 166 endixaprine 2933.39 167 enestebol 2937.99 168 enocitabine 2934.90 169 enoxacin 2933.59 170 enoxaparin sodium 3913.90 171 enoximone 2933.29 172 enprofylline 2939.50 173 epervudine 2934.90 174 epicriptine 2939.60 175 epiestriol 2937.92 176 epimestrol 2937.92 177 epipropidine 2934.90 178 epirubicin 2941.90 179 epitizide 2935.00 180 epsiprantel 2933.59 181 ericolol 2922.50 182 eritrityl tetranitrate 2920.90 183 esorubicin 2941.90 184 etafedrine 2939.40 185 ethynerone 2937.92 186 ethypicone 2933.79 187 etofylline 2939.50 188 etofylline clofibrate 2939.50 189 etoposide 2938.90 190 etrabamine 2934.20 191 evandamine 2934.20 192 exametazime 2928.00 193 famciclovir 2933.59 194 famiraprinium chloride 2933.90 TAR/W/87/Rev.l Page 6 Description HS Code 195 fazarabine 2934.90 196 felbinac 2916.39 197 fenetylline 2939.50 198 fenfluthrin 2916.20 199 Ferric (59 Fe) citrate injection 2844.40 200 Fiacitabine 2934.90 201 flestolol 2924.21 202 fiomoxef 2941.90 203 ludalanine 2845.90 204 fludeoxyglucose (18F) 2844.40 205 lugestone 2937.92 206 luindione 2914.70 207 lumazenil 2933.90 208 luvastatin 2933.90 209 bmidacillin 2941.10 210 :ormebolone 2937.99 211 bsquidone 2933.90 212 :ostriecin 2932.29 213 igadodiamid e 2846.90 214 jgadopenamid e 2846.90 215 gadopentetic acid 2846.90 216 jgadoteri c acid 2846.90 217 jgalantamin e 2939.90 218 |ganciclovi r 2933.59 219 |gemcitabin e 2934.90 220 |gleptoferro n 3913.90 221 jgloximona m 2941.90 222 |glusoferro n 3911.90 223 |glutethimid e 2925.19 224 jgosereli n 2937.99 225 1îalopredon e 2937.22 226 1lydroxycarbamid e 2928.00 227 1lypromellos e 3912.39 228 i bacitabine 2934.90 229 i bafloxacin 2933.90 230 i budilast 2933.90 231 i darubicin 2941.90 232 1tiistreli n 2937.99 233 1tiomidiu m bromide 2933.90 234 1hydroflumethiazid e 2935.00 235 iloprost 2918.19 236 imazodan 2933.29 237 imirestat 2933.21 238 indalpine 2933.39 239 indanidine 2933.29 240 indolidan 2933.79 241 indoprofen 2933.79 242 indoramin 2933.39 243 mocoterone 2937.99 244 insulin argine 2937.99 TAR/W/87/Rev.l Page 7 Description HS Code 245 lodophthalein sodium 2918.90 246 ipazilide 2933.19 247 ipragratine 2933.39 248 ipratropium bromide 2939.90 249 ipsapirone 2934.20 250 irtemazole 2933.29 251 tsamoltan 2933.90 252 isbufylline 2939.50 253 sepamicine 2941.90 254 isoetarine 2922.50 255 isoflupredone 2937.22 256 sometamidium chloride 2933.90 257 isophane insulin 3003.31 258 isoprenaline 2922.50 259 isosorbide 2932.90 260 isosulpride 2935.00 261 itrocainide 2933.40 262 ivermectin 2941.90 263 ivoqualine 2933.40 264 j osamycin 2941.90 265 calafungin 2941.90 266 callidinogenase 3507.90 267 canamycin 2941.90 268 ceracyanin 2938.90 269 cetanserin 2933.59 270 cetazocine 2933.39 271 ketorfanol 2933.40 272 cetotrexate 2933.59 273 chelloside 2938.90 274 citasamycin 2941.90 275 actalfate 2940.00 276 aidlomycin 2941.90 277 amtidine 2933.39 278 aprafylline 2939.50 279 asalocid 2941.90 280 atamoxef 2941.90 281 auroguadine 2925.20 282 auromacrogol 400 3402.13 283 avoltidine 2933.39 284 lemidosul 2930.90 285 lenampicillin 2941.10 286 leuprorelin 2937.99 287 levallorphan 2933.40 288 levisoprenaline 2922.50 289 levodopa 2922.50 290 levomethorphan 2933.40 291 levonorgestrel 2937.92 292 levophenacylmorphan 2933.40 293 levopropylhexedrine 2921.30 294 levorphanol 2933.40 TAR/W/87/Rev.l Page 8 Description HS Code 295 levosulpiride 2935.00 296 libenzapril 2933.79 297 lidamidine 2925.20 298 lifibrol 2918.90 299 lilopristone 2922.50 300 liothyronine 2937.99 301 lisadimate 2922.50 302 lisuride 2939.60 303 lividomycin 2941.90 304 lixazinone 2933.59 305 lobeline 2939.90 306 lodoxamide 2926.90 307 lometraline 2922.29 308 lometrexol 2933.59 309 lomevactone 2932.29 310 lomifylline 2939.50 311 lonapalene 2915.39 312 loprodiol 2905.50 313 loracarbef 2941.90 314 lorajmine 2939.90 315 loreclezole 2933.90 316 lorpiprazole 2933.59 317 losigamone 2932.29 318 losmiprofen 2918.90 319 loxoprofen 2918.30 320 lozilurea 2924.21
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon Et Al
    US008.999632B2 (12) United States Patent (10) Patent No.: US 8,999,632 B2 Falcon et al. (45) Date of Patent: Apr. 7, 2015 (54) METHOD FOR MEASURING ATR (52) U.S. Cl. INHIBITION MEDIATED INCREASES IN DNA CPC ............ G0IN33/5047 (2013.01); G0IN33/68 DAMAGE (2013.01) (58) Field of Classification Search (71) Applicants: Vertex Pharmaceuticals Incorporated, USPC ........................................................ 435/2, 15 Cambridge, MA (US); University of See application file for complete search history. Newcastle Upon Tyne, Newcastle Upon Tyne (GB) (56) References Cited (72) Inventors: Susanna Falcon, Newbury (GB); Philip PUBLICATIONS Reaper, Shillingford (GB); John Kao et al. Inhibition of Gamma-H2AXAfter Ionizing Radiation. As a Pollard, Abingdon (GB); Nicola Curtin, Biological Surrogate of Impaired Upstream DNA Damage Signaling Newcastle upon Tyne (GB); Fiona and Radiosensitivity; Journal of Cancer Molecules, vol. 5, No. 2 Middleton, South Gosforth (GB); Tao (2010) pp. 49-54.* Chen, Suzhou (CN) Buscemi, G., et al., “DNA Damage-Induced Cell Cycle Regulation of Novel Chk2 Phosphoresidues'. Molecular and Cellular Biology, (73) Assignee: Vertex Pharmaceuticals Incorporated, 26(21), (2006), pp. 7832-7845 (DOI: 10.1128/MCB.00534-06). Boston, MA (US) Chen, T., et al., “Targeting the S and G2 checkpoint to treat cancer. s Drug Discovery Today, 17(5/6), (2012), pp. 194-202, (DOI: 10.1016/ - r - j.drudis.2011, 12.009). (*) Notice: Subject to any disclaimer, the term of this Chen, T., et al., “Development of a biomarker of ATR activity in patent is extended or adjusted under 35 surrogate human tissues”, Newcastle University, Poster, Nov. 2012. U.S.C. 154(b) by 0 days.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Treatment for Calcium Channel Blocker Poisoning a Systematic Review
    Clinical Toxicology ISSN: 1556-3650 (Print) 1556-9519 (Online) Journal homepage: http://www.tandfonline.com/loi/ictx20 Treatment for calcium channel blocker poisoning: A systematic review M. St-Onge, P.-A. Dubé, S. Gosselin, C. Guimont, J. Godwin, P. M. Archambault, J.-M. Chauny, A. J. Frenette, M. Darveau, N. Le sage, J. Poitras, J. Provencher, D. N. Juurlink & R. Blais To cite this article: M. St-Onge, P.-A. Dubé, S. Gosselin, C. Guimont, J. Godwin, P. M. Archambault, J.-M. Chauny, A. J. Frenette, M. Darveau, N. Le sage, J. Poitras, J. Provencher, D. N. Juurlink & R. Blais (2014) Treatment for calcium channel blocker poisoning: A systematic review, Clinical Toxicology, 52:9, 926-944, DOI: 10.3109/15563650.2014.965827 To link to this article: http://dx.doi.org/10.3109/15563650.2014.965827 © 2014 The Author(s). Published by Taylor & View supplementary material Francis. Published online: 06 Oct 2014. Submit your article to this journal Article views: 8320 View related articles View Crossmark data Citing articles: 47 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx20 Download by: [Bird Lib Ouhsc] Date: 14 November 2017, At: 06:23 Clinical Toxicology (2014), 52, 926–944 Copyright © 2014 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2014.965827 REVIEW ARTICLE Treatment for calcium channel blocker poisoning: A systematic review M. ST-ONGE,1,2,3 P.-A. DUBÉ,4,5,6 S. GOSSELIN,7,8,9 C. GUIMONT,10 J.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Intracavernous Methoxamine in the Treatment of Priapism
    International Journal of Impotence Research (1998) 10, 257±259 ß 1998 Stockton Press All rights reserved 0955-9930/98 $12.00 http://www.stockton-press.co.uk/ijir Case Report Intracavernous methoxamine in the treatment of priapism J Jara, I Moncada, G Bueno and C Hernandez Urology Department, Hospital General Universitario, Madrid, Spain Methoxamine is an alpha-adrenergic drug, its unique pharmacokinetics and mechanism of action on alpha-1 receptors lead to consider it, similarly to phenylephrine, as a ®rst-choice drug for treating drug-induced or veno-occlusive priapism. The experience obtained with its use in the management of three cases of priapism lasting over 7 h and one case of sustained rigid erection caused during anesthetic induction are reported. Keywords: methoxamine; priapism; intracavernous drug therapy Introduction adrenergic agents. In a later phase, cell ischemia and ®brosis takes place, making the smooth muscle irresponsive to pharmacologic agents. Since the introduction of intracavernous injections In this present study we report on the ef®cacy and of vasoactive drugs in clinical practice, the inci- safety of methoxamine, a selective alpha-1 adrener- dence of priapism have enormously increased, from gic agent, in the treatment of drug-induced pri- 1 being an occasional ®nding to be the most common apism. cause of priapism, according to Lue.2 The incidence of this untoward effect of intra- cavernous injections depends on the drug used, the dose administered and the underlying etiology of Case reports impotence. In a review of the literature,3 papaverine induced priapism in 9.5% of 2314 patients, the Case 1 combination of papaverine plus phentolamine in 5.3% of 2914 patients and PGE1 only in 2.4% of the A 44 y old male presented to the urology department 1284 patients revised.
    [Show full text]
  • Journal of Pharmaceutical and Biomedical Analysis Stability Of
    Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 519–524 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis journal homepage: www.elsevier.com/locate/jpba Short communication Stability of selected chlorinated thiazide diuretics K. Deventer a,∗, G. Baele b, P. Van Eenoo a, O.J. Pozo a, F.T. Delbeke a a DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B-9052 Zwijnaarde, Belgium b Department of Applied Mathematics and Computer Science, Krijgslaan 281, S9, B-9000 Gent, Belgium article info abstract Article history: In sports, diuretics are used for two main reasons: to flush previously taken prohibited substances with Received 6 August 2008 forced diuresis and in sports where weight classes are involved to achieve acute weight loss. A com- Received in revised form 5 November 2008 mon property observed for thiazides is hydrolysis in aqueous media resulting in the formation of the Accepted 6 November 2008 degradation product aminobenzenedisulphonamide. This degradation product can be observed for sev- Available online 13 November 2008 eral thiazides. Because there is limited information regarding the effect of pH, temperature and light on the stability of thiazides, these parameters were investigated for chlorothiaizide, hydrochlorothiazide Keywords: and altizide. For all three compounds the degradation product could be detected after incubation at pH Doping ◦ Urine 9.5 for 48 h at 60 C. At lower pH and temperature the degradation product could not be detected for all Diuretics compounds. When samples were exposed to UV-light altizide and hydrochlorothiazide were photode- Thiazides graded to chlorothiazide. When the degradation rate between the different compounds was compared Sports for a given temperature and pH, altizide is the most unstable compound.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]